Skip to Main Content

Clinical Studies and Protocols

Site Map Investigators Log-in
(AHA-0517) Tissue gene responses to intradermal-gamma (IFN-gamma) in normal and psoriatic patients

 Return to List of Clinical Studies
 Return to List of Protocols for Psoriasis and Skin Diseases
Tissue gene responses to intradermal-gamma (IFN-gamma) in normal and psoriatic patients (AHA-0517)

Principal Investigator:
Asifa Haider M.Pharm, Ph.D.


Contact Information:
Asifa Haider
The Rockefeller University
1230 York Avenue
New York, NY 10021
Enrollment Status:
Closed to Enrollment

Brief Summary of Protocol:
This is a 4–week study that tests the effects of a single dose of IFN-ã in 10 normal volunteers and 10 psoriatic volunteers.

Detailed Description of Protocol:
All subjects will receive two intradermal injections of IFN-ã and equivalent volume of placebo solution at four different anatomical sites.

A skin biopsy will be taken of non-lesional skin in psoriatics or normal skin in normal volunteers prior to injection.

Skin biopsies will be taken at two injection sites 24 hours later.

Blood will be drawn for research purposes at day 0 before and 24 hours after injections.

Volunteers will be seen for follow-ups for additional weeks 1, 2, 3.

Additional blood will be drawn, and two skin biopsies will be taken at any one of those visits only in the event of appearance of psoriasis in psoriatic patients and any skin reaction in normal volunteers at the site of injections.

Clinical assessments and photography will be done at every visit.

What specifically makes a person eligible for the study?
You may be eligible to enter this study:

• Normal volunteers with no evidence of skin disease


• Diagnosis of plaque type psoriasis for at least 6 months

• For women of childbearing potential or in men whose partners may become pregnant, willingness to use an acceptable method of contraception to prevent pregnancy for the duration of the study.


18 years and older

Children permitted to participate:

Potential Benefits.....
This study will not directly benefit the participant. However, since the study may yield important data on the biology of the development of psoriasis it is important to society in general and should be of interest to many participants.

Patients will receive $50 per biopsy for their participation in this study.